These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37726401)

  • 1. Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
    Verrest L; Roseboom IC; Wasunna M; Mbui J; Njenga S; Musa AM; Olobo J; Mohammed R; Ritmeijer K; Chu WY; Huitema ADR; Solomos A; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2023 Nov; 78(11):2702-2714. PubMed ID: 37726401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
    Dorlo TPC; Kip AE; Younis BM; Ellis SJ; Alves F; Beijnen JH; Njenga S; Kirigi G; Hailu A; Olobo J; Musa AM; Balasegaram M; Wasunna M; Karlsson MO; Khalil EAG
    J Antimicrob Chemother; 2017 Nov; 72(11):3131-3140. PubMed ID: 28961737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
    Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
    Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients.
    Verrest L; Wasunna M; Kokwaro G; Aman R; Musa AM; Khalil EAG; Mudawi M; Younis BM; Hailu A; Hurissa Z; Hailu W; Tesfaye S; Makonnen E; Mekonnen Y; Huitema ADR; Beijnen JH; Kshirsagar SA; Chakravarty J; Rai M; Sundar S; Alves F; Dorlo TPC
    Clin Pharmacokinet; 2021 Nov; 60(11):1463-1473. PubMed ID: 34105063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
    Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM; Mbui J; Mohammed R; Olobo J; Ritmeijer K; Alcoba G; Muthoni Ouattara G; Egondi T; Nakanwagi P; Omollo T; Wasunna M; Verrest L; Dorlo TPC; Musa Younis B; Nour A; Taha Ahmed Elmukashfi E; Ismail Omer Haroun A; Khalil EAG; Njenga S; Fikre H; Mekonnen T; Mersha D; Sisay K; Sagaki P; Alvar J; Solomos A; Alves F
    Clin Infect Dis; 2023 Feb; 76(3):e1177-e1185. PubMed ID: 36164254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
    Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S; Chu WY; Sundar S; Mondal D; Das P; Pandey K; Raja S; Rijal S; Roseboom IC; Hamadeh A; Malik PRV; Beijnen JH; Huitema ADR; Sjögren E; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2024 Jul; 79(7):1547-1554. PubMed ID: 38727613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.
    Palić S; Kip AE; Beijnen JH; Mbui J; Musa A; Solomos A; Wasunna M; Olobo J; Alves F; Dorlo TPC
    J Antimicrob Chemother; 2020 Nov; 75(11):3260-3268. PubMed ID: 32780098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
    Dorlo TP; Huitema AD; Beijnen JH; de Vries PJ
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3864-72. PubMed ID: 22585212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.
    Das S; Rani M; Rabidas V; Pandey K; Sahoo GC; Das P
    Br J Pharmacol; 2014 Mar; 171(5):1260-74. PubMed ID: 24670148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R; Musa AM; Njoroge S; Omollo R; Alves F; Hailu A; Khalil EA; Diro E; Soipei P; Musa B; Salman K; Ritmeijer K; Chappuis F; Rashid J; Mohammed R; Jameneh A; Makonnen E; Olobo J; Okello L; Sagaki P; Strub N; Ellis S; Alvar J; Balasegaram M; Alirol E; Wasunna M
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.
    Dorlo TP; Rijal S; Ostyn B; de Vries PJ; Singh R; Bhattarai N; Uranw S; Dujardin JC; Boelaert M; Beijnen JH; Huitema AD
    J Infect Dis; 2014 Jul; 210(1):146-53. PubMed ID: 24443541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
    Dorlo TP; Balasegaram M; Lima MA; de Vries PJ; Beijnen JH; Huitema AD
    J Antimicrob Chemother; 2012 Aug; 67(8):1996-2004. PubMed ID: 22577099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.
    Kip AE; Blesson S; Alves F; Wasunna M; Kimutai R; Menza P; Mengesha B; Beijnen JH; Hailu A; Diro E; Dorlo TPC
    J Antimicrob Chemother; 2021 Apr; 76(5):1258-1268. PubMed ID: 33677546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
    Hailu A; Musa A; Wasunna M; Balasegaram M; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tesfaye S; Makonnen E; Khalil E; Ahmed O; Fadlalla A; El-Hassan A; Raheem M; Mueller M; Koummuki Y; Rashid J; Mbui J; Mucee G; Njoroge S; Manduku V; Musibi A; Mutuma G; Kirui F; Lodenyo H; Mutea D; Kirigi G; Edwards T; Smith P; Muthami L; Royce C; Ellis S; Alobo M; Omollo R; Kesusu J; Owiti R; Kinuthia J;
    PLoS Negl Trop Dis; 2010 Oct; 4(10):e709. PubMed ID: 21049059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.